Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Evoke Pharma, Inc. (EVOK : NSDQ)

• Company Description    Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California. Number of Employees: 3

• Price / Volume Information    Yesterday's Closing Price: $5.18 Daily Weekly Monthly 20 Day Moving Average: 437,115 shares Shares Outstanding: 1.56 (millions) Market Capitalization: $8.07 (millions) Beta: -0.13 52 Week High: $9.88 52 Week Low: $1.94 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.78% -1.04% 12 Week 89.88% 72.40% Year To Date 17.19% 4.64%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 420 STEVENS AVENUE SUITE 230 - SOLANA BEACH,CA 92075 USA ph: 858-345-1494 fax: - dboateng@dkbpartners.net http://www.evokepharma.com

• General Corporate Information    Officers Matthew J. D'Onofrio - Chief Executive Officer Cam L. Garner - Chairman Mark Kowieski - Chief Financial Officer Todd C. Brady - Director Vickie W. Reed - Director Peer Information Evoke Pharma, Inc. (BGMR) Evoke Pharma, Inc. (BBIO) Evoke Pharma, Inc. (IPAH) Evoke Pharma, Inc. (BRL) Evoke Pharma, Inc. (BHC) Evoke Pharma, Inc. (AKRXQ) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-GENERIC DRG Sector: Medical CUSIP: 30049G302 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 1.56 Most Recent Split Date: 8.00 (0.08:1) Beta: -0.13 Market Capitalization: $8.07 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.77 Price/Cash Flow: - Price / Sales: 0.63 EPS Growth vs. Year Ago Period: 33.33% vs. Previous Quarter: -21.57% Sales Growth vs. Year Ago Period: 47.08% vs. Previous Quarter: 21.82% ROE 06/30/25 - -99.48 03/31/25 - -101.91 12/31/24 - -121.73 ROA 06/30/25 - -33.58 03/31/25 - -33.75 12/31/24 - -38.05 Current Ratio 06/30/25 - 1.37 03/31/25 - 1.55 12/31/24 - 1.66 Quick Ratio 06/30/25 - 1.32 03/31/25 - 1.50 12/31/24 - 1.62 Operating Margin 06/30/25 - -42.07 03/31/25 - -43.80 12/31/24 - -52.22 Net Margin 06/30/25 - -42.07 03/31/25 - -43.80 12/31/24 - -52.22 Pre-Tax Margin 06/30/25 - -42.07 03/31/25 - -43.80 12/31/24 - -52.22 Book Value 06/30/25 - 2.93 03/31/25 - 3.91 12/31/24 - 4.74 Inventory Turnover 06/30/25 - 0.82 03/31/25 - 0.61 12/31/24 - 0.69 Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©